Africa Celiac Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Approach, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$12.9 MnPlaceholder estimate
Estimate 2025$14.2 Mn1.5% of the global market
Projected 2034$34.4 Mn 141.6%Adds $20.2 Mn over 9 forecast years
CAGR 2025–203410.3%Faster than 56% of 180 Pharmaceuticals markets here
Key players5
Africa is 1.5% of the global market.
Among regions, the largest is North America at $458.6 Mn.
3 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Africa Celiac Disease Treatment Market Analysis Executive Summary
Celiac disease treatment today is a gluten-free diet, with new medicines in development to protect the gut from gluten.
Key segments of the celiac Disease Treatment market include approach (Gluten-Free Diet Products, Enzyme Therapies and Tolerance Therapies) and age (Children and Adults).
Africa Celiac Disease Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Africa Celiac Disease Treatment Market Dynamics
Market Growth Drivers
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the celiac Disease Treatment market. Biosimilars are widening access.
Opportunity
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the celiac Disease Treatment market room to grow.
Market Restraints
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the celiac Disease Treatment market.
Competitive Landscape for Celiac Disease Treatment Market in Africa
The celiac Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Celiac Disease Treatment Market in Africa
Celiac Disease Treatment in Africa: rules, payment and research
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3], SAHPRA (South Africa)[4] and NAFDAC (Nigeria)[5]. How care is paid for in some of these countries: universal health insurance (Egypt)[6], the SHA (Kenya)[7], planned National Health Insurance (South Africa)[8] and out of pocket and the NHIA (Nigeria)[9]. ClinicalTrials.gov lists 3 studies on Celiac Disease Treatment that are recruiting, active or about to start in Africa.[10]
[10]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for celiac Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Approach
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Takeda
7.2 Anokion
7.3 Teva Pharmaceutical
7.4 ImmunogenX
7.5 Dr. Schar
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The celiac Disease Treatment market can be segmented based on various criteria, including approach, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Celiac Disease Treatment right now, from free public sources.
Clinical trials
3 active trials in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco
Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Celiac Disease Treatment market in Africa?
Placeholder estimate: about $14.2 Mn in 2025, rising to about $34.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Celiac Disease Treatment market in Africa growing?
Placeholder estimate: about 10.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Celiac Disease Treatment market report cover?
The report splits the market by approach (Gluten-Free Diet Products, Enzyme Therapies, Tolerance Therapies, Diagnostics), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Celiac Disease Treatment market?
Key players include Takeda Pharmaceutical Company Ltd, Anokion, Teva Pharmaceutical, ImmunogenX and Dr. Schar.
What is driving the Celiac Disease Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the celiac Disease Treatment market. Biosimilars are widening access.
Who regulates Celiac Disease Treatment in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Celiac Disease Treatment are running in Africa?
3 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Celiac Disease Treatment?
PubMed lists 1,496 papers on Celiac Disease Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.